Home Situations ALNY — Price diverging from similar companies
Situation · 2026-04-24

ALNY — Price diverging from similar companies

Premium Faces Test Amid Volatility and Confidence Risks

Updated 2026-04-23 · Ref: Biotechnology
Key metrics — 2026-04-23
Peer score
56
Quality pct
73
Valuation pct
13
52w drawdown
-36.1%
21d vs sector
+1.6%
Peer group
Biotechnology
Situation summary

Alnylam’s premium valuation persists despite top-tier ROIC and 85% revenue growth. Profitability and commercial momentum remain intact. However, high volatility and a -42.5% drawdown signal fragile market confidence. A more defensible premium would require stable sentiment and consistent delivery on ambitious guidance.

Published by AssetNext · 2026-04-21

All companies with this signal today

View full list: Price diverging from similar companies →

Related pages for ALNY
Full peer analysis for Alnylam Pharmaceuticals, Inc. →Similar companies to ALNYALNY peersAll ALNY comparisonsRussell 1000 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-04-23 Price diverging from similar companies 56 -36.1% +1.6%
2026-04-20 Price diverging from similar companies 57 -36.7% -0.6%
2026-04-16 Price diverging from similar companies 57 -34.8% +4.1%
2026-04-14 Strong businesses outperforming 57 -30.9% +10.6%

See ALNY's full peer analysis

Break down ALNY's structural position across all peer dimensions with the interactive app.

Open ALNY in AssetNext →